首页 > IVF > In-depth Analysis of Repeated IVF Failure in Thailand: Hospital Selection & Coping Strategies

In-depth Analysis of Repeated IVF Failure in Thailand: Hospital Selection & Coping Strategies

Systematic analysis of medical causes and hospital-related factors for repeated IVF failure in Thailand, covering embryo quality, uterine environment, immune abnormalities, and laboratory conditions. Provides systematic post-failure investigation pathways and key points for hospital selection evaluation, offering scientific decision-making reference for patients.

Title block (without h1)

In-depth Analysis of Repeated IVF Failure in Thailand Hospital Selection Evaluation · Systematic Investigation Pathway · Personalized Coping Strategies
Beginning: Real consultation scenario (case of failure cause)
Real Consultation Scenario — A 41-year-old patient, AMH 0.8, completed 2 cycles at a fertility center in Thailand, with a total of 5 eggs retrieved, forming 2 blastocysts (4AA, 4AB). Both transfers resulted in no implantation. Hysteroscopy indicated a maximum endometrial thickness of 7.0 mm, suspicious for chronic endometritis. The patient's records showed that the embryos did not undergo PGT-A testing, and the ovarian stimulation protocol was a conventional antagonist protocol. This is a typical consultation for "recurrent implantation failure," where the causes are often not singular.
Module A: Direct answer to the question

I. Core Causes of Repeated IVF Failure in Thailand

Recurrent implantation failure (RIF) is not uncommon among the IVF population in Thailand. From a medical perspective, the main causes are concentrated in the following four levels:

  • Embryo Factors (highest proportion): Chromosomal aneuploidy is the primary cause, especially when female age is ≥38 years, the rate of euploid embryos significantly decreases. Even blastocysts with high morphological scores may have a 30%–50% chance of chromosomal abnormalities.
  • Uterine Factors: Including decreased endometrial receptivity, chronic endometritis, intrauterine adhesions, thin endometrium (<7 mm), adenomyosis, etc.
  • Immune and Coagulation Factors: Abnormal NK cell activity, thyroid autoantibodies, antiphospholipid antibody syndrome, thrombophilia, etc.
  • Hospital Laboratory and Technical Factors: Stability of embryo culture environment, culture media batch variation, laboratory quality control system, PGT technical experience, etc.
Module B: Why does this problem occur

II. Why Repeated Failure Occurs – A Systematic Medical Analysis

From a reproductive medicine perspective, repeated failure is rarely caused by a single factor; it is usually the result of multiple factors叠加.

2.1 Embryo Chromosomal Abnormalities: Age is the Core Variable

Increasing female age directly leads to a rise in the aneuploidy rate of eggs. At age 38, the euploid embryo rate is about 40%–50%, dropping to 20%–30% by age 42. Some hospitals in Thailand do not routinely recommend PGT-A for older patients, leading to the transfer of chromosomally abnormal embryos and repeated failure.

2.2 Displacement of the Window of Implantation (WOI)

In natural cycles or hormone replacement therapy cycles, the endometrial receptive period (WOI) varies individually. ERA testing reveals that about 25%–30% of RIF patients have a displaced WOI, requiring personalized adjustment of the transfer timing.

2.3 Chronic Endometritis (CE) is Underestimated

The incidence of CE in the RIF population is about 30%–60%, and it is easily missed by routine ultrasound and hysteroscopic morphological examination. Diagnosis requires endometrial biopsy + CD138 immunohistochemistry. Some fertility centers in Thailand do not include CE screening as a routine procedure.

2.4 Laboratory Conditions: The Invisible Variable

The stability of the embryo culture environment (temperature, pH, gas concentration), culture media batch variation, and operational experience differ between hospitals. For patients with repeated failure, laboratory conditions are a factor that needs to be evaluated.

Module C: Doctor's perspective

III. How Reproductive Specialists View Repeated Failure

In clinical decision-making, reproductive specialists usually investigate step by step in the order of "embryo – uterus – immunity – male factor," rather than advising patients to blindly switch hospitals or doctors.

  • If the patient is ≥38 years old and has not undergone PGT-A, the doctor will prioritize recommending PGT-A testing for remaining embryos or considering a PGT-A strategy in a new cycle.
  • For uterine factors, hysteroscopy is the gold standard, and endometrial biopsy + CD138 staining to rule out CE is also recommended.
  • Immune factors are controversial in mainstream reproductive medicine, but after repeated failure and exclusion of other causes, a comprehensive immune workup (NK cells, T cell subsets, thyroid antibodies, antiphospholipid antibodies, etc.) can be informative.
  • The doctor will also assess whether the ovarian stimulation protocol is personalized: for older patients or those with low ovarian reserve, the antagonist protocol may not be optimal; PPOS or mild stimulation protocols might be more suitable.
Module G: Most easily overlooked details

IV. Most Easily Overlooked Details

Detail 1: Embryo Culture Media Batch Variation — Different batches of culture media from the same hospital can affect embryo development. Top-tier laboratories conduct rigorous batch testing, but not all centers do this.
Detail 2: Male Sperm DNA Fragmentation Index (DFI) — When DFI >30%, even if routine semen analysis is normal, it can affect blastocyst formation and implantation rates. Some hospitals in Thailand do not include DFI as a routine test.
Detail 3: Vitamin D Levels — Vitamin D deficiency is correlated with recurrent implantation failure. Supplementation is recommended when 25-OH vitamin D levels are <30 ng/mL.
Detail 4: Endometrial Microbiome — Dysbiosis of the endometrial microbiota (reduced proportion of Lactobacillus) may affect receptivity and has gained increasing attention in recent years.
Module H: Most common pitfalls

V. Most Common Cognitive and Behavioral Pitfalls

  • Pitfall 1: Believing morphologically good embryos are good embryos — Morphological grading and chromosomal euploidy are not the same. A 4AA blastocyst still has a high probability of chromosomal abnormalities, especially in older women.
  • Pitfall 2: Immediately switching hospitals after repeated failure — Switching hospitals without a systematic investigation may repeat the same failure path at the new center.
  • Pitfall 3: Skipping hysteroscopy and proceeding directly to the next transfer — Hysteroscopy is the gold standard for evaluating the uterine cavity; about 30% of RIF patients have occult lesions detected by hysteroscopy.
  • Pitfall 4: Blindly pursuing PGT-A (PGT-A) — PGT-A cannot solve all problems. It offers limited benefit for younger patients with low aneuploidy rates and carries risks of mosaic misdiagnosis.
  • Pitfall 5: Neglecting a comprehensive male evaluation — In cases of repeated failure, male sperm DFI, Y chromosome microdeletion, and karyotype should all be included in the investigation.
Module I: Actual process – Systematic investigation pathway after failure

VI. Systematic Investigation Process After Repeated Failure

The following investigation pathway is based on clinical consensus in reproductive medicine. It is recommended to proceed step by step to avoid missing key links.

1
Embryo Factor Investigation — If frozen embryos remain, prioritize PGT-A testing; if no frozen embryos, consider PGT-A strategy in a new cycle. Also, review past embryo development records (fertilization rate, cleavage rate, blastocyst formation rate).
2
Uterine Factor Investigation — Hysteroscopy + endometrial biopsy (CD138 immunohistochemistry to rule out CE) + ERA testing (to assess whether WOI is displaced). Recommended on days 18–22 of the menstrual cycle (or days 12–14 of an HRT cycle).
3
Immune and Coagulation Factor Investigation — Peripheral blood NK cell count and activity, T cell subsets, thyroid function + antibodies, antiphospholipid antibody panel, protein S/C, antithrombin III, homocysteine.
4
Male Factor Investigation — Sperm DNA fragmentation index (DFI), Y chromosome microdeletion, karyotype analysis. DFI testing requires 2–3 days of abstinence; prolonged abstinence should be avoided.
5
Hospital and Technical Evaluation — Review the ovarian stimulation protocol, laboratory culture conditions, and PGT technical platform. If necessary, consult a third-party reproductive medicine specialist for a case review.
Module L: Interpretation of key indicators

VII. Interpretation of Key Diagnostic Indicators

Indicator Reference Range Significance in Repeated Failure
AMH >1.0 ng/mL Reflects ovarian reserve; low values suggest limited egg retrieval number but do not directly determine embryo quality
Basal FSH <10 IU/L Elevation indicates decreased ovarian response, requiring personalized adjustment of the stimulation protocol
Antral Follicle Count (AFC) >5–7 per ovary More直观 reflection of ovarian reserve than AMH; bilateral AFC <5 indicates poor ovarian response
Sperm DNA Fragmentation Index (DFI) <15% excellent; 15–30% moderate; >30% poor DFI >30% significantly affects blastocyst formation and implantation rates, even if routine semen analysis is normal
CD138+ Endometrial Biopsy Negative Positive indicates chronic endometritis, requiring antibiotic treatment before transfer
ERA Test Receptive window If non-receptive, transfer timing needs adjustment (advance or delay by 12–24 hours)
NK Cells (Peripheral Blood) <12%–15% (varies by lab) Excessively high activity may be associated with recurrent implantation failure, but should be interpreted in conjunction with other indicators
Module Q: Frequently asked questions

VIII. Frequently Asked Questions

Q1: Should I switch hospitals after repeated failure?
It is not recommended to switch before completing a systematic investigation. If a comprehensive investigation has been done and a clear cause is identified (e.g., laboratory limitations, unsuitable stimulation protocol), switching may be considered. Otherwise, switching may repeat the same outcome.
Q2: Why does it fail even with good quality embryos?
Good morphological grading ≠ normal chromosomes. Additionally, endometrial receptivity, immune factors, and subclinical endometritis can all lead to transfer failure. Each factor needs to be investigated.
Q3: How to evaluate the laboratory conditions of a Thai hospital?
It can be assessed from several dimensions: ability to perform extended blastocyst culture to day 6–7; routine use of time-lapse incubators; PGT technology platform (mainly NGS); whether the lab is ISO certified; experience of the embryology team, etc.
Q4: How long should I wait before the next transfer after repeated failure?
The investigation phase usually takes 1–2 menstrual cycles. If issues like CE or immune abnormalities are found, treatment generally requires 1–3 months before another transfer. Consecutive cycle transfers are not recommended; allow adequate recovery time for the endometrium.
Q5: Is PGT-A necessary?
For patients aged ≥38, with recurrent implantation failure, or a history of chromosomal abnormality pregnancies, PGT-A offers clear benefits. However, PGT-A cannot detect mosaicism or single gene disorders (requires PGT-M), and carries risks of false positives/negatives. The decision should be personalized.
Knowledge graph coverage: related entities naturally integrated
AMHFSHLHAntral Follicle Count Semen AnalysisChromosome TestingGenetic Counseling HysteroscopyEmbryo CulturePGT-A Frozen Embryo TransferLuteal SupportReproductive Specialist Embryology LabBlastocyst CultureERA Testing NK CellsDFIChronic Endometritis
Ending: Risk reminder (randomly selected)
Risk Reminder: Repeated IVF failure is a complex medical issue involving multiple intersecting factors. The investigation pathway and interpretations provided in this article are based on current clinical consensus in assisted reproductive medicine, but individual patient conditions vary. All treatment decisions should be made under the guidance of a reproductive medicine specialist. It is not recommended to self-diagnose or adjust plans based on online information. Personalized evaluation is crucial, especially for older patients, those with very low ovarian reserve, or those with concurrent autoimmune diseases.
Practitioner perspective | Naturally integrated

This article is compiled based on clinical observations in reproductive medicine and knowledge bases, and does not serve as direct medical advice. For specific conditions, it is recommended to consult a reproductive medicine specialist with complete medical records.

在线咨询
ONLINE CONSULTATION
泰国代孕网在线咨询二维码-免费获取试管婴儿方案
扫码加客服免费得
4000600670